Evidence map›Paper›PMID 42502396›Full record

ArticleiScience2026

MZT2A drives epithelial-mesenchymal transition in lung adenocarcinoma via the LGALS3BP/ITGB1/TGF-β/smad2 axis.

Yizhuo Li, Yi Yang, Zhe Zhang, Rui Wang, Zongang Liu, Huanxi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yizhuo LiDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, China.
Yi YangDeparment of Laboraroy Animal Science, China Medical University, Shenyang, China.
Zhe ZhangDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, China.
Rui WangDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, China.
Zongang LiuDepartment of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Huanxi WangDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high mortality of lung adenocarcinoma (LUAD) is largely attributed to its metastatic propensity; therefore, elucidating novel mechanisms driving metastasis is crucial for developing diagnostic and therapeutic strategies. This study aimed to elucidate the function and mechanism of MZT2A in the metastasis of LUAD. Analysis of clinical samples and public databases revealed that MZT2A is highly expressed in LUAD tissues and significantly associated with lymph node metastasis, advanced stage, and poor prognosis.

Indexed as

epithelial-mesenchymal transitionITGB1LGALS3BPLung adenocarcinomaMZT2ATGF-β pathway

Identifiers

PMID42502396
PMCPMC13400767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.